Recent News
20 October, 2022
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
05 Jan, 2022
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
30 Nov, 2021
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
15 Nov 2021
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T
Media Contact
If you are a member of the media and would like to speak with T-knife, please contact us at media@t-knife.com.
